DB-1303/BNT323(HER2)

DB-1311/BNT324(B7-H3)

DB-1305/BNT325(TROP2)

BioNTech is a global leader in next-generation immunotherapy, pioneering innovative treatments for cancer, infectious diseases, and other serious conditions. Headquartered in Germany, BioNTech has operations across five continents and a global workforce of over 6,000employees. In recent years, BioNTech has strategically enhanced its clinical pipeline through global partnerships, including collaboration with our Company to add next-generation ADC assets into its oncology portfolio. Our partnership with BioNTech, which originated from the two companies’ meetings at industry conferences, is driven by a shared strategy to develop innovative therapies that couldpotentially complement or replace chemotherapy, addressing the needs of cancer patients across the entire disease continuum.

DB-1324

DualityBio have entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the agreement, DualityBio will grant GSK an exclusive option to obtain a license to develop and commercialize DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau)

DB-1312(B7-H4)

BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, BeiGene is expediting development of its diverse pipeline of novel therapeutics through internal capabilities and collaborations. BeiGene’s growing global team of more than 10,000 colleagues spans five continents. BeiGene is investing in impactful therapeutic modalities such as ADCs to complement its pipeline in solid tumors.

We have entered into a strategic partnership with BeiGene, where we granted to BeiGene a global license to develop and commercialize DB-1312, our in-house discovered B7-H4- targeted ADC. This collaboration enables BeiGene to advance DB-1312 globally in conjunction with its internally discovered ADC assets, leveraging our industry-leading research capabilities and BeiGene’s end-to-end ADC manufacturing expertise and creating a synergistic approach to drug development.

Proprietary ADC Platform

DualityBio entered into an exclusive license agreement with Adcendo ApS, a Denmark-based biotech company focused on the development of breakthrough ADCs for the treatment of underserved cancers, pursuant to which we granted to Adcendo an irrevocable (subject to the termination provisions therein), exclusive, royalty-bearing and sublicensable license under certain of our technologies, including payload-linkers derived from our proprietary DITAC platform, to develop, manufacture and commercialize Adcendo’s uPARAP-ADC product worldwide.

 DB-1418/AVZO-1418 （EGFR/HER3 Bispecific）

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. Avenzo Therapeutics, Inc. and DualityBio have entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC, globally (excluding Greater China).

DB1303（HER2）

DualityBio and Shenyang Sansheng Pharmaceutical Co., Ltd., a subsidiary of 3SBio, have entered into a collaboration agreement regarding the HER2 ADC drug DB-1303. According to the agreement, 3SBio will obtain the commercialization rights for multiple indications of DualityBio's HER2 ADC drug DB-1303 in Mainland China, Hong Kong, and Macau.